BridgeBio Stock Hits 1-Year High as Attruby Rx Numbers Double

BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to beat a 2025 sales consensus of $86 million.